The gene editing approach is really exciting. We need technology that will be able to deal with problems like these large genes, said Dr. Jean Bennett, a University of Pennsylvania researcher who helped test Luxturna at the Childrens Hospital of Philadelphia.
Date: Mar 04, 2020
Category: Health
Source: Google
FDA Approves First Gene Therapy for Inherited Disease
During the more than 12 years of innovative research with dedicated collaborators near and far, Ive witnessed the dramatic improvement in vision in many patients who would have otherwise lost their sight, commented Jean Bennett, M.D. Ph.D., the F.M. Kirby Professor of Ophthalmology in thePerelma
Date: Dec 20, 2017
Category: Health
Source: Google
Gene therapy for rare form of blindness wins US approval
University of Pennsylvania researcher Dr. Jean Bennett said she and her husband, Dr. Albert Maguire, first imagined using genetic medicine to treat retinal blindness in the mid-1980s. But it took decades to develop the science and technology, with the first animal tests in 2000 and the first human t
Date: Dec 19, 2017
Category: Health
Source: Google
Why FDA's approval of a gene therapy to treat form of blindness is such a big deal
That is until four years ago, when Beth found Dr. Jean Bennett and her husband, Dr. Albert Maguire. The couple has been dedicated to reversing hereditary blindness for two decades. They say this new treatment could be a turning point.
Date: Oct 13, 2017
Category: Health
Source: Google
Seeing hope: FDA panel considers gene therapy for blindness
"It's usually a surprise that they have a blind child," said Dr. Jean Bennett, a University of Pennsylvania researcher who with her husband, Dr. Albert Maguire, led testing at the Children's Hospital of Philadelphia. The couple designed an obstacle course to test vision after treatment, and the FDA
Date: Oct 09, 2017
Category: Health
Source: Google
Biogen (BIIB), Univ. of Pennsylvania Enter Development Collaboration Covering Multiple Gene Therapy Technologies
Biogen will work with James Wilson, M.D., Ph.D., Professor of Medicine and Pediatrics, and Director of Penns Gene Therapy Program, and Jean Bennett, M.D., Ph.D., Professor of Ophthalmology and Cell and Developmental Biology and Director of the Center for Advanced Retinal and Ocular Therapeutics. Bonior vice president, Cell & Gene Therapy at Biogen. Joining forces with gene therapy pioneers, James Wilson and Jean Bennett, further enables Biogen to approach the technology from a powerful perspective. By exploring next-generation delivery in various tissues such as the retina, skeletal musc
Date: May 16, 2016
Category: Business
Source: Google
Biogen may invest up to $2B to fund gene therapy research at U Penn
The company will work with two recognized leaders in gene therapy at U Penn's Perelman School of Medicine: James Wilson, M.D., Ph.D., Professor of Medicine and Pediatrics and Director of Penn's Gene Therapy Program and Jean Bennett, M.D., Ph.D., Professor of Ophthalmology and Cell and Development Bi
Date: May 16, 2016
Category: Business
Source: Google
Biogen Turns To UPenn Gene Therapy Pioneers in Wide-Ranging Alliance
Jean Bennett and James Wilson have worked for decades of at UPenn on gene therapy, a method of ferrying genetic instructions into the body to produce what could become a long-lasting treatment for various diseases. Those effects are as yet hypothetical; no gene therapy has been approved in the U.S.